References
- Hehir MK, Silvestri NJ. Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology. Neurol Clin. 2018;36(2):253–260.
- Fichtner ML, Jiang R, Bourke A, et al. O’Connor KC. autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol. 2020;11:776.
- De Haard J, Dreier T, Ulrichts P, et al. Use of FcRn antagonists for treatment of generalized myasthenia gravis. World Intellectual Property Organization patent WO 2019/110823 A1. 2019 June. Available in: https://patents.google.com/patent/WO2019110823A1/en.
- McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology. 2010;34(3):171–183.
- Deenen JC, Horlings CG, Verschuuren JJ, et al. The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscul Dis. 2015;2(1):73–85.
- Phillips LH. The epidemiology of myasthenia gravis. Ann N Y Acad Sci. 2003;998(1):407–412.
- Heldal AT, Owe JF, Gilhus NE, et al. Seropositive myasthenia gravis: a nationwide epidemiologic study. Neurology. 2009;73(2):150–151.
- Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114–122.
- Farmakidis C, Pasnoor M, Dimachkie MM, et al. Treatment of myasthenia gravis. Neurol Clin. 2018;36(2):311–337.
- Alabbad S, AlGaeed M, Sikorski P, et al. Monoclonal antibody-based therapies for myasthenia gravis. BioDrugs. 2020;34(5):557–566.
- Murai H. Japanese clinical guidelines for myasthenia gravis: putting into practice. Clinical and Experimental Neuroimmunology. 2015;6(1):21–31.
- Melzer N, Ruck T, Fuhr P, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German neurological society. J Neurol. 2016;263(8):1473–1494.
- Sussman J, Farrugia ME, Maddison P, et al. The association of British neurologists’ myasthenia gravis guidelines. Ann N Y Acad Sci. 2018;1412(1):166–169.
- Brazil. Ministry of health. Ordinance n 11, of 2022 May 23. Approves the Clinical Protocol and Therapeutic Guidelines for Myasthenia Gravis. Available from: http://conitec.gov.br/images/Protocolos/20220530_PORTAL_PCDT_Miastenia_Gravis.pdf
- Bedlack RS, Sanders DB. How to handle myasthenic crisis. Essential steps in patient care. Postgrad Med. 2000;107(4):211–222.
- Roper J, Fleming ME, Long B, et al. Myasthenia gravis and crisis: evaluation and management in the emergency department. J Emerg Med. 2017;53(6):843–853.
- Food and Drug Administration [Internet]. United States: drugs@FDA: FDA-Approved Drugs. Vyvgart (efgartigimod). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761156s000lbl.pdf. Acceced on 2022 Feb 24
- Clinical Trials [Internet]. United States: clinical Trials. Efgartigimod; [cited 2022 Feb 24]. Available from: https://clinicaltrials.gov/ct2/home
- Ober RJ, Martinez C, Lai X, et al. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci U S A. 2004;101(30):11076–11081.
- Gable KL, Guptill JT. Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis. Front Immunol. 2020;10:3052.
- Xiao JJ. Pharmacokinetic models for FcRn-mediated IgG disposition. J Biomed Biotechnol. 2012;2012:282989.
- Patel DA, Puig-Canto A, Challa DK, et al. Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model. J Immunol. 2011;187(2):1015–1022.
- Vaccaro C, Zhou J, Ober RJ, et al. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 2005 Oct;23(10):1283–1288.
- Yi JS, Guptill JT, Stathopoulos P, et al. B cells in the pathophysiology of myasthenia gravis. Muscle Nerve. 2018;57(2):172–184.
- Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372–4386.
- National Institute for Health. National Center for Advancing Translational Sciences. Inxight Drugs. Efgartigimod alfa. [cited 2022 Apr 6]. Available in: https://drugs.ncats.io/substance/961YV2O515
- Fields JK, Sundberg EJ. Structure of human IgG1 Fc. 7LBL code. Protein Data Bank. 2021; 10.2210/pdb7LBL/pdb
- JF H, Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661–e2673.
- JF H, Bril V, Vu T, et al.Safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis (ADAPT): a multicentre, randomized, placebo-controlled, phase 3 trial [published correction appears in Lancet Neurol. Lancet Neurol. 2021;20(7):526–536. 20(8):e5
- Howard J, Brill V, and Vu T, et al., Tolerability, and efficacy of efgartigimod in patients with generalized myasthenia gravis: interim results of the ADAPT+ study. American Academy of Neurology. AAN Annual Meeting, Boston. Abstract 2770; [cited 2022 May 24]. Available in: https://index.mirasmart.com/aan2022/PDFfiles/AAN2022-002770.html
- YA H. Efgartigimod: first Approval. Drugs. Erratum in: Drugs. 2022 Mar 30; 2022;823:341–348.
- Jeong A, Min JH, Kang YK, et al. Factors associated with quality of life of people with Myasthenia Gravis. PLoS One. 2018;13(11):e0206754.
- Cioncolini D, Casali S, Ginanneschi F, et al. Major motor-functional determinants associated with poor self-reported health-related quality of life in myasthenia gravis patients. Neurol Sci. 2016;37(5):717–723.
- Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021;14:1756286421997381.
- Zuercher AW, Spirig R, Baz Morelli A, et al. Next-generation Fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev. 2019;18(10):102366.
- Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27(3):171–178.
- Guidon AC, Juel VC. Efgartigimod: a novel antibody depletion therapy in myasthenia gravis. Neurology. 2019;92(23):1079–1080.
- Argenx. Argenx announces positive topline phase 3 data from ADAPT-SC study evaluating subcutaneous efgartigimod for generalized myasthenia gravis. News release. March 22, 2022. Available from: https://www.argenx.com/sites/default/files/media-documents/argenx_ADAPT-SC_TLR_Press_Release.pdf. Accessed 2022 May 23.
- Schneider-Gold C, Gilhus NE. Advances and challenges in the treatment of myasthenia gravis. Ther Adv Neurol Disord. 2021;14:17562864211065406.
- Bril V, Benatar M, Andersen H, et al. Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial. Neurology. 2021;96(6):e853–e865.
- Clinical Trials [Internet]. United States: clinical Trials. Rozanolixizumab; [cited 2022 May 24]. Available from: https://clinicaltrials.gov/ct2/home
- Clinical Trials [Internet]. United States: clinical Trials. Nipocalimab; [cited 2022 May 24]. Available from: https://clinicaltrials.gov/ct2/home
- Yan C, Duan RS, Yang H, et al. Therapeutic effects of batoclimab in Chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase II study. Neurol Ther. 2022;11(2):815–834.
- Clinical Trials [Internet]. United States: clinical Trials. Batoclimab; [cited 2022 May 24]. Available from: https://clinicaltrials.gov/ct2/home
- Sand KM, Bern M, Nilsen J, et al. Unraveling the Interaction between FcRn and Albumin: opportunities for Design of Albumin-Based Therapeutics. Front Immunol. 2015 Jan 26;5:682
- Md AH, Deb KP, Hossain MA, et al. Correlation between serum cholesterol and serum albumin level in childhood nephrotic syndrome. Urol Nephrol Open Access J. 2016;3. 00086.
- Dalakas MC. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev Clin Immunol. 2022 Jun 23;1–11. doi:10.1080/1744666X.2022.2082946.